Application of Helz2 in drugs for preventing and treating tumors
The present disclosure provides a vector containing a target sequence that targets and interferes with Helicase with zinc finger 2 (Helz2), the target sequence comprising one or more of the following sequences: SEQ ID No. 5: 5′-GCTATCAAGTCTGTCACTACT-3′; SEQ ID No. 6: 5′-GCACGATGCTGTATGGCTTTG-3′; SEQ ID No. 7: 5′-GGGCCTCATTGACACTCAAAG-3′.
1 . A vector containing a target sequence that targets and interferes with Helicase with zinc finger 2 (Helz2), the target sequence comprising one or more of the following sequences:
SEQ ID No. 5:
5′-GCTATCAAGTCTGTCACTACT-3′;
SEQ ID No. 6:
5′-GCACGATGCTGTATGGCTTTG-3′;
SEQ ID No. 7:
5′-GGGCCTCATTGACACTCAAAG-3′.
2 . The vector according to claim 1 , wherein the vector is a biologically acceptable vector and is one of lentiviral vector complex, adenovirus, adeno-associated virus, N-acetylgalactosamine (GalNAc), liposomes (LNPs), polymers, and oncolytic viruses.
3 . A method for establishing an Helz2 knockout mouse model, comprising:
performing Helz2 knockout on fertilized mouse eggs by using CRISPR/Cas9 technique with an sgRNA sequence; and
obtaining a systemic Helz2 knockout homozygous mouse model through microinjection and breeding of the fertilized mouse eggs,
wherein the sgRNA sequence comprises one or more of the following sequences:
SEQ ID No. 1:
5′-GCCCCAGAGTTACCAGATGGAGG-3′;
SEQ ID No. 2:
5′-CCTACACCCGACAGAGGTGTAGG-3′;
SEQ ID No. 3:
5′-AGCAGTGACAGTCTTATGGGTGG-3′;
SEQ ID No. 4:
5′-GGCATACAGAGGATTGCCACAGG-3′.
4 . An sgRNA sequence for establishing an Helz2 knockout animal model, comprising one or more of the following sequences:
SEQ ID No. 1:
5′-GCCCCAGAGTTACCAGATGGAGG-3′;
SEQ ID No. 2:
5′-CCTACACCCGACAGAGGTGTAGG-3′;
SEQ ID No. 3:
5′-AGCAGTGACAGTCTTATGGGTGG-3′;
SEQ ID No. 4:
5′-GGCATACAGAGGATTGCCACAGG-3′.